Equities analysts expect Evolent Health Inc (NYSE:EVH) to report earnings per share of ($0.05) for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have issued estimates for Evolent Health’s earnings. The highest EPS estimate is ($0.02) and the lowest is ($0.12). Evolent Health posted earnings of ($0.04) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 25%. The business is scheduled to report its next quarterly earnings report on Tuesday, February 26th.

On average, analysts expect that Evolent Health will report full-year earnings of ($0.10) per share for the current financial year, with EPS estimates ranging from ($0.20) to ($0.04). For the next year, analysts anticipate that the business will report earnings of $0.23 per share, with EPS estimates ranging from $0.00 to $0.38. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that cover Evolent Health.

Evolent Health (NYSE:EVH) last issued its earnings results on Tuesday, November 6th. The technology company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. Evolent Health had a negative return on equity of 2.18% and a negative net margin of 9.05%. The firm had revenue of $150.16 million for the quarter, compared to the consensus estimate of $142.94 million. During the same quarter in the previous year, the company posted ($0.18) earnings per share. The business’s quarterly revenue was up 38.6% compared to the same quarter last year.

A number of research analysts have commented on the company. Piper Jaffray Companies restated an “overweight” rating and issued a $34.00 target price on shares of Evolent Health in a research note on Wednesday, November 7th. ValuEngine downgraded Evolent Health from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 1st. Wells Fargo & Co boosted their target price on Evolent Health from $26.00 to $34.00 and gave the company an “outperform” rating in a research note on Wednesday, November 7th. Canaccord Genuity boosted their target price on Evolent Health from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Thursday, September 13th. Finally, Cowen upped their price target on Evolent Health from $29.00 to $35.00 and gave the stock an “outperform” rating in a research note on Thursday, September 13th. One investment analyst has rated the stock with a sell rating and twelve have given a buy rating to the stock. Evolent Health presently has a consensus rating of “Buy” and a consensus price target of $31.73.

In other news, CEO Frank J. Williams sold 3,878 shares of the company’s stock in a transaction dated Monday, August 20th. The stock was sold at an average price of $24.00, for a total transaction of $93,072.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Thomas Peterson III sold 30,000 shares of the company’s stock in a transaction dated Thursday, August 30th. The stock was sold at an average price of $25.00, for a total value of $750,000.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 163,592 shares of company stock valued at $4,255,571. 4.82% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in EVH. US Bancorp DE boosted its stake in Evolent Health by 6.1% during the 3rd quarter. US Bancorp DE now owns 40,225 shares of the technology company’s stock valued at $1,142,000 after purchasing an additional 2,301 shares during the period. Metropolitan Life Insurance Co. NY boosted its stake in Evolent Health by 12.6% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 22,031 shares of the technology company’s stock valued at $464,000 after purchasing an additional 2,459 shares during the period. FDx Advisors Inc. boosted its stake in Evolent Health by 21.9% during the 3rd quarter. FDx Advisors Inc. now owns 14,936 shares of the technology company’s stock valued at $424,000 after purchasing an additional 2,682 shares during the period. State Board of Administration of Florida Retirement System boosted its stake in Evolent Health by 16.9% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 21,773 shares of the technology company’s stock valued at $458,000 after purchasing an additional 3,150 shares during the period. Finally, Swiss National Bank boosted its stake in Evolent Health by 3.4% during the 3rd quarter. Swiss National Bank now owns 100,800 shares of the technology company’s stock valued at $2,863,000 after purchasing an additional 3,300 shares during the period.

NYSE EVH traded up $0.51 on Friday, reaching $24.96. The stock had a trading volume of 800,963 shares, compared to its average volume of 885,055. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.50 and a quick ratio of 2.50. Evolent Health has a 1 year low of $10.65 and a 1 year high of $29.05. The company has a market capitalization of $1.98 billion, a P/E ratio of -35.66 and a beta of 1.50.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.

Recommended Story: How a Put Option Works

Get a free copy of the Zacks research report on Evolent Health (EVH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.